Latest news with #Pathlight
Hamilton Spectator
4 days ago
- Business
- Hamilton Spectator
U.S. court case sees Saks Global accuse lender of contributing to Bay's demise
TORONTO - Saks Global is putting some of the blame for Hudson's Bay's demise on one of the faltering department store's top lenders. A letter Saks Global filed earlier this month in a New York lawsuit against Pathlight Capital LP said the lender was a 'direct cause' of Hudson's Bay's inability to secure 'much-needed financing.' 'As a result of these actions and inactions by Pathlight, HBC was forced to initiate restructuring proceedings under the Companies' Creditors Arrangement Act (CCAA) in Canada,' Saks Global chief legal officer Andrew Woodworth said in a March 26 letter to Pathlight's managing director. 'Pathlight's ongoing intransigence further frustrated HBC's CCAA proceedings, and, on March 21, 2025, forced HBC to announce a near total liquidation.' After the letter was sent on March 26, Hudson's Bay determined that it was not going to find the money it needed to keep all of its stores alive. With little hope left, Canada's oldest company decided to take its liquidation even further and is due to sell off all merchandise at its 80 stores and 16 under the Saks name by Sunday. The Saks stores in Canada were operated through a license Hudson's Bay had with Saks Global. Neither company nor lawyers for the firms or Pathlight immediately responded to a request for comment. Saks Global was formed last year, when Hudson's Bay purchased Neiman Marcus and Bergdorf Goodman and spun them out with its existing Saks Fifth Avenue into a new company. Court documents say that transaction was made possible in part because Pathlight agreed to release Saks Global from obligations under a loan the Bay had in exchange for millions in payments. Now, Pathlight is suing Saks Global because it has yet to be paid US$8.8 million it is owed. Saks is refusing to pay the sum because it says Pathlight 'cannot and should not benefit from its own actions,' which hurt the Bay. At the start of Hudson's Bay's creditor protection case in Canada, Pathlight was listed as a secured creditor owed more than $95 million. This report by The Canadian Press was first published May 30, 2025.
Winnipeg Free Press
4 days ago
- Business
- Winnipeg Free Press
U.S. court case sees Saks Global accuse lender of contributing to Bay's demise
TORONTO – Saks Global is putting some of the blame for Hudson's Bay's demise on one of the faltering department store's top lenders. A letter Saks Global filed in a New York lawsuit against Pathlight Capital LP says the lender's failure to support Hudson's Bay and its move to allegedly deprive it of much-needed financing led it to seek creditor protection. Saks Global was formed last year, when Hudson's Bay purchased Neiman Marcus and Bergdorf Goodman and spun them out with its existing Saks Fifth Avenue into a new company. Court documents say that transaction was made possible in part because Pathlight agreed to release Saks Global from obligations under a loan the Bay had in exchange for millions in payments. Now, Pathlight is suing Saks Global because it has yet to be paid US$8.8 million it is owed. Monday Mornings The latest local business news and a lookahead to the coming week. The U.S. court battle comes as Hudson's Bay and its Canadian Saks stores approach their final weekend of liquidation sales before the locations close for good. This report by The Canadian Press was first published May 30, 2025.
Yahoo
4 days ago
- Business
- Yahoo
U.S. court case sees Saks Global accuse lender of contributing to Bay's demise
TORONTO — Saks Global is putting some of the blame for Hudson's Bay's demise on one of the faltering department store's top lenders. A letter Saks Global filed in a New York lawsuit against Pathlight Capital LP says the lender's failure to support Hudson's Bay and its move to allegedly deprive it of much-needed financing led it to seek creditor protection. Saks Global was formed last year, when Hudson's Bay purchased Neiman Marcus and Bergdorf Goodman and spun them out with its existing Saks Fifth Avenue into a new company. Court documents say that transaction was made possible in part because Pathlight agreed to release Saks Global from obligations under a loan the Bay had in exchange for millions in payments. Now, Pathlight is suing Saks Global because it has yet to be paid US$8.8 million it is owed. The U.S. court battle comes as Hudson's Bay and its Canadian Saks stores approach their final weekend of liquidation sales before the locations close for good. This report by The Canadian Press was first published May 30, 2025. Tara Deschamps, The Canadian Press Sign in to access your portfolio
Yahoo
5 days ago
- Business
- Yahoo
Lender Pathlight Sues Saks After Clearing the Way for the Neiman's Deal
Saks Global has fallen out with Pathlight Capital, which helped clear the way for the luxury retailer's $2.7 billion acquisition of Neiman Marcus last year, but has now sued the company, claiming it's still owed $8.8 million in fees. In turn, Saks alleges that Pathlight's 'lack of good faith' led to the Hudson's Bay restructuring. More from WWD Hudson's Bay Signs Lease Deal With Chinese Billionaire Saks Global's Emily Essner on Navigating Luxury Amid Uncertainty Resurrecting Hudson's Bay, in a Limited Way While the money at stake is relatively small, the suit, filed May 21 in New York Supreme Court, comes at a delicate time for Saks, which declined Wednesday to comment on the case. The deal to acquire Neiman's marked the start of Saks' attempt to reset the U.S. luxury retail scene. The combination has spurred on big changes at both Neiman's and Saks, generated millions in costs and led to a luxury storefront on Amazon. But vendors have chafed at past-due bills and new, slower payment terms. Bondholders, meanwhile, have soured on debt the company raised just six months ago, trading some of the $2.2 billion in junk bonds used to fund the Neiman's acquisition down to as low as 38 cents on the dollar. The Pathlight suit, which shines a light on how the retail buyout came together last year, is one more moving part and potential expense. Pathlight has been a partner to Saks for years, extending it and its former parent company, Hudson's Bay Co., a senior secured term loan facility in 2020. The suit said that Hudson's Bay and Saks Global requested that Pathlight 'restructure the outstanding debt of HBC and…Saks Global,' a switch that was 'critical to facilitating the complex purchase-and-spinoff transaction' with Neiman's. In return for amending the credit facility and giving Hudson's Bay a $65.6 million term loan, Pathlight said Saks agreed to pay it $5 million on Jan. 6. That payment was made. But Pathlight said Saks also agreed to pay $4.4 million in March and another $4.4 million in April if its term loans to Hudson's Bay were not repaid. 'Pathlight fully performed its obligations,' the suit said. 'But the term loans were not repaid; therefore, Saks Global was required to timely pay the second and final installments but has failed to do so.' The suit includes a March 26 letter from Saks' chief legal officer Andrew Woodworth to Pathlight refusing to pay the remaining $8.8 million and alleging that the lender tripped up Hudson's Bay's efforts to refinance the term loan, which would have gotten the company off the hook for the follow-up payments. 'Pathlight failed to reasonably support opportunities presented by HBC, and such failure and lack of good faith cooperation has been the direct cause for HBC's inability to secure this much-needed refinancing. As a result of these actions and inactions by Pathlight, HBC was forced to initiate restructuring proceedings under the Companies' Creditors Arrangement Act (CCAA) in Canada,' which is akin to bankruptcy. 'Pathlight's ongoing intransigence further frustrated HBC's CCAA proceedings, and, on March 21, 2025, forced HBC to announce a near total liquidation,' Woodworth wrote for Saks. 'Pathlight has not acted in good faith, has frustrated HBC's ability to refinance the specified term loan transactions, and has thereby deprived HBC of the opportunity to obtain much-needed financing. Pathlight cannot and should not benefit from its own actions, which deprived HBC of its ability to finance its operations.' Pathlight's managing director Matt Williams shot back the next day and said 'Pathlight's alleged bad-faith dealings with HBC…have no bearing on Saks Global's obligation to pay the structuring fee.' Now the two are in court and Saks' lawyers have promised to respond to the company by July 22. In Saks world, that's a lifetime away. In the meantime, the retailer owes bondholders a $120 million interest payment on June 30, needs to start paying vendors for new shipments and also has to start making back payments to brands who were owed money for shipments made over the past two years. Best of WWD The Biggest Legal Battles Shaping the Fashion Industry Today PETA Asks Lululemon About Slaughterhouse Practices China's Livestreaming Star Viya Fined $210 Million for Tax Evasion Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Business Wire
27-05-2025
- Business
- Business Wire
SAGA Diagnostics® Announces U.S. Commercial Launch of Pathlight™ at ASCO 2025, Setting a New Standard for Ultra-sensitive and Early MRD Detection
MORRISVILLE, N.C.--(BUSINESS WIRE)-- SAGA Diagnostics, a pioneer in blood-based cancer detection and precision medicine redefining the standard for ultra-sensitive and early molecular residual disease (MRD) detection, today announced the U.S. commercial launch of its Pathlight test for the detection of residual disease and recurrence at the 2025 American Society for Clinical Oncology (ASCO) Annual Meeting in Chicago, May 30 - June 3. Pathlight's baseline detection rate was 96% overall, and 94% in estrogen receptor-positive (ER+) breast cancer, which suggests clinical advantages over first generation ctDNA assays. Pathlight is a first-of-its-kind, multi-cancer MRD platform, initially indicated for early breast cancer, that uses structural variants (SVs) as biomarkers. SVs are well-established hallmarks of cancer, arising from and contributing to genomic instability and oncogenesis. SVs, including breakpoints and rearrangements, are highly tumor- and patient-specific and often reflect the underlying tumor biology making them informative biomarkers for tracking disease. Pathlight combines whole genome sequencing and proprietary algorithms and informatics optimized for the identification of stable SV breakpoints, generating a personalized genomic fingerprint for each tumor, which are subsequently orthogonally validated and tracked utilizing proprietary multiplex digital PCR to enable rapid, precise, efficient and quantitative MRD detection from a simple blood draw. 'By tracking structural variants — stable, unique, and tumor-defining fingerprints of each patient's cancer — Pathlight enables interception of recurrence at its most treatable and potentially curable stage,' commented Roopom Banerjee, Executive Chairman of SAGA Diagnostics. 'Our goal is to deliver the most accurate, trusted results that provide assurance and support confident, informed treatment decisions. Our published, peer reviewed data demonstrates the clinical validity of Pathlight in breast cancer and its potential power across all solid tumors and heme malignancies. SAGA has further partnered with leading clinicians, institutions, and biopharma to bring Pathlight to market and best serve patients.' The clinical validity of Pathlight was established with samples collected in the TRACER (cTdna evaluation in eaRly breAst canCER) study, published in Clinical Cancer Research 1 in January 2025. In this retrospective analysis of 100 patients with stage I–III breast cancer of all subtypes receiving standard-of-care neoadjuvant and adjuvant therapy Pathlight demonstrated best-in-class clinical performance – with 100% sensitivity and 100% specificity, and a 13.7-month lead time to recurrence as confirmed by clinical presentation or imaging. Notably, Pathlight's baseline detection rate was 96% overall, and 94% in estrogen receptor-positive (ER+) breast cancer, which suggests clinical advantages over first generation ctDNA assays. Pathlight also delivered unparalleled sensitivity – breaking the 1ppm barrier and offers the potential to detect MRD at the earliest possible opportunity, to support individualized intervention directed towards cure. 'The vast majority of breast cancer patients are diagnosed with ER+ disease, and up to 25% will experience recurrence – often many years after completing curative-intent treatment,' said David Cescon, MD, PhD, medical oncologist and clinician scientist at Princess Margaret Cancer Centre, University Health Network and senior author of the paper. 'We know that continued improvement in outcomes for people diagnosed with early breast cancer will require a shift towards more individualized treatment. There is a critical need for MRD testing that is both ultra-sensitive and ultra-specific, to enable long-term surveillance and risk-aligned treatment decisions for each patient.' Pathlight has been submitted for US Reimbursement via the MolDX Program and is analytically validated across multiple cancer types. The test is already being used successfully in clinical studies by top pharmaceutical companies and at preeminent academic institutions and national cancer centers. SAGA Diagnostics and its collaborators will be presenting three abstracts highlighting Pathlight's performance in breast cancer, ovarian cancer and soft-tissue sarcoma at ASCO: Abstract #11511| June 1 | 9:00 a.m. – 12:00 p.m. CDT Title: Potential of tumor-informed ctDNA as an early predictor for relapse in advanced ovarian cancer Abstract #5574 | June 2 | 11:30 a.m. – 1:00 p.m. CDT Title: Detecting ctDNA using personalized structural variants to forecast recurrence in localized soft tissue sarcoma (STS) Abstract #3057 | June 2 | 1:30 p.m. – 4:30 p.m. CDT Title: NeoCircle: Investigating circulating tumor DNA dynamics as a predictor of survival in primary breast cancer SAGA will also be showcasing the capabilities and partnership opportunities of Pathlight at its booth (#36150) during the conference. References Elliott MJ, Howarth K, Main S, et al. Ultrasensitive detection and monitoring of circulating tumor DNA using structural variants in early-stage breast cancer. Clin Cancer Res. 2025;31(8):1520-1532. doi:10.1158/ About Pathlight Pathlight™ is a next-generation, tumor-informed multi-cancer molecular residual disease (MRD) test, initially indicated for commercial testing in breast cancer. Pathlight uses whole genome sequencing to identify large-scale genomic changes, called structural variants (SVs), and tracks them over time using a unique combination of NGS and digital PCR, enabling industry-leading sensitivity and specificity. By optimizing for SVs that are stable, truncal biomarkers, Pathlight enables ultrasensitive recurrence detection and treatment response monitoring from early stage to metastatic disease. Developed and marketed by SAGA Diagnostics, the test has been submitted for US Reimbursement via the MolDX Program and is being used in clinical studies by multiple top 10 pharmaceutical companies and leading academic institutions and national cancer centers. For more information, About SAGA Diagnostics SAGA Diagnostics® is redefining the early detection of molecular residual disease (MRD), empowering treatment decisions with greater insight and confidence. Pathlight™, the company's flagship product, is an ultra-sensitive, blood-based, multi-cancer MRD test that is now available for commercial use in the U.S. for patients with breast cancer. SAGA is partnering with pharmaceutical and biotechnology companies, as well as commercial entities to support early through late-stage cancer development programs across a range of cancer types. SAGA's headquarters and CLIA-certified laboratory is located in the heart of the life science ecosystem in Research Triangle Park, North Carolina. SAGA Diagnostics combines world-class genomic expertise with a leadership team deeply experienced in molecular residual disease (MRD), all aligned around a compelling mission of intercepting cancer at the earliest stages when it's most treatable. For more information,
